Stockreport

Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hours [Seeking Alpha]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hoursRepros Therapeutics (NASDAQ:RPRX)announces that the Eu [Read more]